Abstract: Over the last decade, clinical registries have significantly contributed to the pool of evidence that supports management decisions in patients with multiple sclerosis. Being the largest international registry of multiple sclerosis and neuroimmunological disorders, MSBase collects demographic, clinical and limited paraclinical information from patients managed in different regions and under various circumstances. In this review, we will provide an overview of its published output, with focus on the information with impact on the management of multiple sclerosis.
Introduction
The introduction of beta-interferon therapy for relapsing multiple sclerosis (MS) in the 1990s created many great changes for people living with the disease and their clinicians. This was the start of the era of MS disease-modifying therapies. The MS Nurse profession grew from the need to teach and support injection therapies, and specialised MS management clinics emerged in many neurological services. The growing need to track outcomes in large numbers of MS patients resulted in the development of MS-specific electronic databases and visualisation platforms for clinical care. A leading system, named iMed, was developed by the pharmaceutical company Serono in 2000. The popularity of iMed convinced Serono to develop an innovative web-based tool to accumulate codified MS patient datafiles from iMed programs into an online registry, MSBase. After a successful development phase, MSBase was handed over to MS clinicians in 2004 and the Registry was incorporated as an independent notfor-profit company based in Australia. 1 It has grown to be the largest international MS registry, with over 63,000 patient records from 132 member clinics in 35 countries (www.msbase.org, accessed on 28 March 2019). The success of MSBase is founded on a few well-established principles. Most importantly, all investigators agree to collect a well-defined minimum dataset. The vision of MSBase is highly democratic, exemplified by the fact that every member can request the composite dataset for analyses. At the same time, each individual member remains in control of their contributed dataset in MSBase and can refuse or permit access to their portion of the data on a project-by-project basis. As the MSBase governance principles are transparent and strong, investigators all over the world remain confident to engage, contribute data, perform analyses and debate the results and outcomes vibrantly. One major advantage of MSBase is that participation is voluntary and self-selected -this means that participants are actively interested in collection and analysis of high-quality clinical outcomes data in MS. The density and the quality of the collected data are assured through a transparent data quality process, with focus on syntactic accuracy, consistency and believability of the recorded information. 2 MSBase is registered with World Health Organization International Clinical Trials Registry Platform (ACTRN12605000455662) and it was approved by Melbourne Health Human Research Ethics Committee and by each site's institutional review board as required.
In this topical review, we will summarise the published output from MSBase, with focus on the studies with impact on the management of MS. The summarised evidence is a combination of original studies and results that are confirmatory of other previously published original studies. density and quality for the routinely collected clinical measures. In March 2019, it has held almost 550,000 disability scores (Expanded Disability Status Scale (EDSS)), 86% of which also had recorded Kurtzke Functional System Scores, with the mean inter-score interval of 5.7 months -a data density that is comparable to most clinical trials. The larger participating academic centres have been particularly successful in generating high-quality data. 2 While such selective registry is not suited for quantification of populationbased incidence and prevalence of MS and other diseases, it has enabled the research of other, highly focused questions related to MS epidemiology and phenomenology.
For instance, first MS symptoms tend to be reported earlier in patients living at higher latitude. 3 Relapses are more frequently observed during early spring months, both in the northern and the southern hemispheres, with the peak of the relapse incidence following the local trough of ultraviolet radiation. The lag between the UV radiation trough and relapse peak tends to be longer in lower latitudes (by 28 days for every 10° of latitude, 95% confidence interval (95% CI) 3-54, n = 9811). 4 Younger age and female sex are associated with higher risk of relapses, and male sex is associated with a marginally faster accumulation of disability. 5 The female-to-male ratio is distinctly lower in patients with primary progressive multiple sclerosis (PPMS; 1.2:1) than in patients with relapseonset MS with very low relapse activity (2.2:1; n = 12,451). 6 The phenotype of a relapse is partly determined by patient characteristics such as disease duration, age and sex. 7 Patients also tend to re-present with relapses that involve neurological domains affected by their previous relapses.
From the global perspective, the features of MS have continued to change. In agreement with other published works, 8, 9 MSBase has shown that the time to significant disability milestones 10 or secondary progressive multiple sclerosis (SPMS) 11 has markedly increased over the last two decades. Whether this shift is driven by the advance in MS immunotherapy remains to be determined.
Effectiveness and sequencing of MS therapies
Patients and their neurologists share the same goalto minimise the impact of MS through informed choice of immunotherapy with respect to patients' individual circumstances. This goal has now become feasible, as long-term continuous exposure to MS immunotherapies is associated with substantial reduction of the risk of disability worsening (hazard ratio (HR) = 0.60, 95% CI = 0.43-0.82, n = 14,717). 12 At the same time, this knowledge becomes the source of indication bias that is inherent in any observational dataset from treated patients. Among the several established analytical methods that can mitigate indication bias, propensity score-based methods have become commonly used in MS research. 13 These methods have been utilised extensively in several other areas of medicine, where they are an accepted standard practice. 14, 15 In scenarios in which randomised clinical trials would not be feasible or ethical, several large observational databases have been generating evidence that elucidates relative effectiveness among the currently available immunotherapies. Analyses typically aim at replicating the results of pivotal trials in order to establish external validity with the used methodology, before researchers proceed to explore questions that had not previously been studied in trial settings. For instance, analyses from MSBase first showed that the effectiveness of the two doses of subcutaneous interferon β-1a is similar, thus replicating the results of the PRISMS trial. 16 Further analyses replicated the results of head-to-head comparative trials of first-line injectable immunomodulatory therapies. 17 Subsequently, we demonstrated that escalation of therapy is superior to 'horizontal' treatment switching, particularly among patients who experienced on-treatment disease activity on another injectable agent. 18, 19 The differences between different classes of immunotherapies are relatively less pronounced in patients who were previously treatment-naïve. 20 Among the two most commonly used escalation strategies, natalizumab is associated with superior control of relapses (HR = 0.6, 95% CI = 0.4-0.8) and a greater chance of improvement in neurological function than fingolimod (HR = 2.8, 95% CI = 1.7-4.6, n = 578). 21 Using data from the Australian product familiarisation programme, the effect of cladribine on relapse activity was most comparable with that of fingolimod. 22 Among the most potent immunotherapies, alemtuzumab and natalizumab are associated with similar effects on relapse frequency, while natalizumab seems superior to alemtuzumab in the rate of confirmed improvement of neurological function (HR = 0.35, 95% CI = 0.20-0.59, n = 361). 23 Several questions addressed with the MSBase data relate to specific treatment scenarios. For example, commencement of fingolimod within 2 months from discontinuation of natalizumab prevents post-treatment reactivation of the disease. 24 This observation was subsequently replicated in a randomised clinical trial 25 and was associated with an almost immediate practice change, also seen in the MSBase registry, as clinicians rapidly reduced the washout period between natalizumab cessation and fingolimod commencement. Among patients who discontinue MS immunotherapies, the risk of disease reactivation is relatively lower in older males with greater pre-existing disability. On the other hand, a greater risk of disability progression is associated with older age and previous on-treatment progression of disability. 26, 27 The advances in the use of observational data have enabled clinicians to make informed treatment decisions in the multiple situations that are not directly addressed in randomised clinical trials. While such complementary evidence is important for closing the gap between studies of treatment efficacy and the need for personalised treatment approaches, it puts a greater demand on the clinical and academic community -reviewers, editors and readers alike -as multiple sources of bias are often present in the data. Therefore, for studies using observational data, thoughtful analytical designs are mandatory. 28 
Progression of disability across MS phenotypes
All clinical MS phenotypes can be associated with accumulation of disability, whether secondary to or independent from relapses. 29 As evidenced by numerous clinical trials, episodic inflammatory activity has traditionally been viewed as the preventable feature of MS. Recently, clinical trials have shown that some of the immunotherapies are also capable of slowing disability progression, in particular in patients with radiological evidence of focal inflammation. 30, 31 The MSBase collaboration has recently generated complementary evidence, which highlights the role that clinically manifest episodic inflammation can play in the decisions about treatment of progressive disease forms. Overall, exposure of a cohort with PPMS to any immunotherapy approved for relapsing-remitting MS (with an overrepresentation of injectable agents) was not associated with improved disability outcomes over the short term. 32 However, in PPMS stratified by superseded relapse activity, greater persistence on any immunotherapies was associated with decreased risk of disability progression among patients who were experiencing relapses (active PPMS, also known as progressive-relapsing MS) 33 but not in those with purely progressive MS phenotype. 34 We estimated that uninterrupted treatment of active PPMS can be associated with up to 30% reduction in the frequency of sustained disability progression events when compared to no exposure to immunotherapy (HR = 0.66, 95% CI = 0.54-0.90, n = 553).
A similar association is observed in advanced relapseonset MS (identified with restricted gait, such as EDSS step 4 or 6). After patients have reached important disability milestones, faster disability accrual is associated with a higher frequency of relapses and is, in turn, mitigated by a greater exposure to high-efficacy immunotherapies. 35 This therapeutic benefit is even evident in advanced MS, delaying progression from EDSS step 6.0 to 6.5 (9% decreased risk of progression for every 25% of time spent on immunotherapy, 95% CI = 1%-16%, n = 880).
Cohorts with advanced relapse-onset MS are typically enriched for patients with SPMS. We have developed an operationalised definition of SPMS, which is suited for use as an inclusion criterion or an outcome in clinical studies. 36 This definition provides researchers with an instrument to identify patients with SPMS in a reproducible manner, independent from therapeutic decisions and with less delay than a diagnosis assigned by a clinician. Using this definition to select patients with wellestablished SPMS, we did not find an overall effect of pooled disease-modifying therapies (available for relapsing-remitting MS) on disability progression in SPMS. 37 However, high persistence on these therapies is associated with slower rate of disability progression among those patients with SPMS who are experiencing relapses (β = −0.028 to −0.019, 95% CI = −0.045 to −0.001, n = 661), but not those without any clinical signs of episodic inflammation (β = −0.008 to −0.006, 95% CI = −0.027 to 0.010, n = 960). 38 This observation corroborates the findings from the trial of siponimod in SPMS, in which relapsing SPMS was associated with more pronounced response to the studied therapy than non-relapsing SPMS. 31 Interestingly, disability trajectories after patients have been diagnosed with SPMS do not seem to be contingent on relapse frequency or exposure to immunotherapies during the early stages of relapsing-remitting MS. 38 Taken together, the above observations suggest that the course of MS is highly variable over time. The imminent deterioration of neurological function is co-determined by ongoing episodic inflammatory activity and its modulation with appropriate immunotherapy. 39 Importantly, the onset of progressive disease, which still poses a significant therapeutic problem, can be substantially delayed or even prevented by early and proactive immunotherapy (HR = 0.76 for commencement of highefficacy therapy ⩽5 vs >5 years from disease onset, 95% CI = 0.66-0.88, n = 638). 40 
Outcome measures
Prevention and reversal of neurological disability are presently the goals of immunotherapy for MS.
Objective evaluation of physical disability relies mainly on neurological examination -a complex assessment process that requires substantial training and experience and is not free from subjective bias. 41 This is reflected by the relatively low stability of EDSS scores in individuals during the initial 4 years from MS onset. 42 In patients with longer disease durations, temporal stability of the recorded EDSS scores improves.
In an attempt to maximise the reliability of disability outcomes, both for the use in observational registries as well as in clinical trials, we have evaluated a number of definitions of confirmed disability progression. 43 For the definitions most commonly used in clinical trials, the proportion of progression events sustained at 5 years were 70% and 74% when 3-or 6-month confirmation period was used, respectively. Using a 12-month confirmation increased the stability of the events to 80%. The characteristics associated with a higher likelihood of recovery from disability progression events were female sex, young age and relapsing MS course.
While more robust means of quantitating MS-related disability are clearly needed, the accessibility of EDSS and its compatibility with standard neurological assessment make it currently the most widespread MS disability scale. Its capacity to serve as a reliable outcome in observational registries, while accounting for the variability in assessment as well as the variability of the disease, can be improved with the use of advanced analytical approaches, such as latent class modelling and Bayesian methods. 44, 45 Prognostics Prognostics of MS is complicated by the high variability of its course (both inter-individual and over time). Prior disability trajectories are only loosely associated with future disability accrual, an observation that is replicated throughout different stages of the disease. 35, 46 MSBase has contributed to the prediction of clinically definite MS after its first clinical presentation. 47 In keeping with the analyses of focused, deeply phenotyped cohorts, 48 our predictive models developed in a large population at multiple, predominantly tertiary MS centres, identified greater disability, younger age, presence of oligoclonal bands in the cerebrospinal fluid (CSF) and higher magnetic resonance imaging (MRI) lesion load and activity at clinically isolated syndrome as being predictive of earlier diagnosis of clinically definite MS. 47 These predictors were enriched for female sex and multifocal disease onset in paediatric-onset MS. 49 Complementary to this, older age and involvement of motor function at first presentation of MS were associated with a greater risk of worsening of disability. 50 Frequent relapses during the course of clinically definite MS are predictive of disability both over the short term and the long term. Phenotyping of relapses reveals that those most commonly associated with poorer disability outcomes present with pyramidal, cerebellar and sphincteric symptoms and signs. 51, 52 Interestingly, on-treatment break-through relapses are more important predictors of future disability worsening (an ontreatment relapse is associated with a mean 0.86-step increase in EDSS) than the relapses that occur off any immunotherapy (an off-treatment relapse is associated with a mean 0.05-step increase in EDSS). 51 In pregnancy, the most reliable predictor of post-partum risk of relapses is pre-partum relapse activity (β = 14.1, 95% CI = 9.1-21.9, n = 893 pregnancies). 53 In summary, the results from the MSBase registry have contributed to the global effort to identify associations that help predict future disease activity and disability in patient groups and in specific clinical scenarios. Our next task is to integrate these associations into comprehensive predictive models, capable of estimating risks (and their distributions) in individual patients, with focus on individualised treatment decisions. Our initial effort at personalised prediction of treatment response, using only the demographic, clinical and limited paraclinical predictors available in MSBase, was well replicated in a non-overlapping cohort from the Swedish MS Registry (79%-96% predictive accuracy of the prediction of relapses and changes in EDSS over up to 4 years). 54 Further advances in the individual prediction of treatment response will require not only very large prospectively collected datasets but also novel analytical approaches. 45 
Limitations
The main limitation of the MSBase registry rests with the observational nature of the recorded data. 55 Data acquisition integrated into clinical practice is associated with increased opportunity for error, mostly due to the lack of primary data verification, reliance on traditional outcome measures, reporting bias and heterogeneity among the participating centres. 28 We have implemented systematic measures to mitigate the impact of these sources of error and bias, including a standardised data quality and density procedure, 2 Neurostatus training and adjusting analyses for study centre or country. The self-selected participation of the MSBase sites, which are mainly subspecialised academic MS centres and clinics, may impact negatively on generalisability of the generated evidence.
We have therefore implemented a standardised assessment of representativeness of the recorded data 2 and our analyses are typically accompanied by sensitivity analyses that explore generalisability of our findings in different clinical contexts. Finally, reproducibility of study results is an important attribute of the process of discovery, and in many studies, we have used discovery and validation cohorts to demonstrate the robustness of newly generated evidence.
Future directions
The MSBase Foundation is completing the launch of a new data entry system in 2019, in order to meet the needs of MS outcomes data generation in the future. A number of key challenges and opportunities await. Most importantly, the new system allows the technical integration of new data sources via a robust application programming interface (API). There is a trend towards patient self-generated data from active and passive monitoring tools connected to the web, and these will supplement tracking of neurological disability using physician-administered scales such as the EDSS score. The new system also easily allows patient-reported outcomes such as quality of life and, importantly, productivity measures to be integrated with the minimum dataset.
Another area which will undoubtedly advance rapidly in the next 5 years is MRI monitoring. There is a great demand to implement serial MRI measures such as the change in lesion load or brain volume as markers of disease phenotype and treatment effect. MSBase is developing infrastructure that will enable integration of volumetric MRI data with demographic and clinical information. As part of this development, a number of complex problems will need to be addressed, including standardisation of scanning protocols across multiple sites and modelling of systematic measurement error.
With the introduction of a large number of new MS disease-modifying therapies, safety monitoring and early identification of serious risks have become a subject of high importance. To meet this challenge, several MS registries including the Swedish, Danish, French (OFSEP) and Italian national registries, and MSBase, are now implementing a protocol for systematic collection of key safety and pregnancy outcomes. The European Medicines Agency is moving towards considering the generated data for future post-approval safety studies.
Reliable analytical approaches are critical for translation of observational data into evidence. Led by the Clinical Outcomes Research unit (CORe) and together with other academic partners, including, the French and the Danish national registries, MSBase has been working towards standardising analytical frameworks used in the research of observational data. Furthermore, new goals are calling for new analytical approaches. As an example, implementation of Bayesian methods will help us move the focus from observations made in large cohorts to disease outcomes in individual patients.
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